199 related articles for article (PubMed ID: 20586802)
21. Management of muscle haematomas in patients with severe haemophilia in an evidence-poor world.
Sørensen B; Benson GM; Bladen M; Classey S; Keeling DM; McLaughlin P; Yee TT; Makris M
Haemophilia; 2012 Jul; 18(4):598-606. PubMed ID: 22151135
[TBL] [Abstract][Full Text] [Related]
22. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition.
Berntorp E; Collins P; D'Oiron R; Ewing N; Gringeri A; Négrier C; Young G
Haemophilia; 2011 Jan; 17(1):e202-10. PubMed ID: 20825500
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of rFVIIa versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico.
Rodríguez-Zepeda MDC; González L; Bravo A; Pompa T; Silva S; Paredes R; García J; Ramos M; Wilkinson L; Lamotte M
Value Health Reg Issues; 2018 Dec; 17():164-173. PubMed ID: 30317158
[TBL] [Abstract][Full Text] [Related]
24. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.
Petrini P; Klementz G
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S143-6. PubMed ID: 9819046
[TBL] [Abstract][Full Text] [Related]
25. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
26. The need for speed in the management of haemophilia patients with inhibitors.
Salek SZ; Benson GM; Elezović I; Krenn V; Ljung RC; Morfini M; Remor E; Santagostino E; Sørensen B
Haemophilia; 2011 Jan; 17(1):95-102. PubMed ID: 20398071
[TBL] [Abstract][Full Text] [Related]
27. Treatment of hemophilia.
Rodeghiero F
Ric Clin Lab; 1985; 15(4):289-303. PubMed ID: 3914697
[TBL] [Abstract][Full Text] [Related]
28. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
29. Modern management of haemophilic arthropathy.
Raffini L; Manno C
Br J Haematol; 2007 Mar; 136(6):777-87. PubMed ID: 17341263
[TBL] [Abstract][Full Text] [Related]
30. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations.
Perry D; Berntorp E; Tait C; Dolan G; Holme PA; Laffan M; Lassila R; Mumford A; Pasi J; Wilde J; Will A; Yee TT
Haemophilia; 2010 Jan; 16(1):80-9. PubMed ID: 19780845
[TBL] [Abstract][Full Text] [Related]
31. Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors.
Tran HT; Sørensen B; Rea CJ; Bjørnsen S; Ueland T; Pripp AH; Tjønnfjord GE; Holme PA
Haemophilia; 2014 May; 20(3):369-75. PubMed ID: 24251535
[TBL] [Abstract][Full Text] [Related]
32. Management of difficult-to-treat inhibitor patients.
Giangrande PL; Escobar MA
Haemophilia; 2010 May; 16 Suppl 3():52-7. PubMed ID: 20586803
[TBL] [Abstract][Full Text] [Related]
33. The perspective of patients with haemophilia with inhibitors and their care givers: preferences for treatment characteristics.
Brown TM; Pashos CL; Joshi AV; Lee WC
Haemophilia; 2011 May; 17(3):476-82. PubMed ID: 21091851
[TBL] [Abstract][Full Text] [Related]
34. Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study.
Zanon E; Milan M; Gamba G; Ambaglio C; Saggiorato G; Spiezia L; Montani N; Prandoni P
Thromb Res; 2015 Dec; 136(6):1299-302. PubMed ID: 26505666
[TBL] [Abstract][Full Text] [Related]
35. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents.
Mehta R; Parameswaran R; Shapiro AD
Haemophilia; 2006 Dec; 12 Suppl 6():54-61. PubMed ID: 17123395
[TBL] [Abstract][Full Text] [Related]
36. Conservative treatment of hemarthrosis for prevention of hemophilic synovitis.
Ribbans WJ; Giangrande P; Beeton K
Clin Orthop Relat Res; 1997 Oct; (343):12-8. PubMed ID: 9345199
[TBL] [Abstract][Full Text] [Related]
37. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.
Leissinger CA
Am J Hematol; 2004 Oct; 77(2):187-93. PubMed ID: 15389908
[TBL] [Abstract][Full Text] [Related]
38. A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.
Teitel J; Berntorp E; Dolan G; Fischer K; Gringeri A; Kessler C; Lambert T; Leissinger C; Nemes L; Shima M
Haemophilia; 2011 May; 17(3):516-21. PubMed ID: 21371181
[TBL] [Abstract][Full Text] [Related]
39. U.S. survey of surgical capabilities and experience with surgical procedures in patients with congenital haemophilia with inhibitors.
Shapiro A; Cooper DL
Haemophilia; 2012 May; 18(3):400-5. PubMed ID: 22168829
[TBL] [Abstract][Full Text] [Related]
40. Prevention of bleeding in hemophilia patients with high-titer inhibitors.
Leissinger CA; Konkle BA; Antunes SV
Expert Rev Hematol; 2015 Jun; 8(3):375-82. PubMed ID: 25937074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
